IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: US RE37,504

Dated: January 8, 2002

Atty Docket No.: 62-575

REISSUE PATENT OF:

LIN

TITLE: OPHTHALMIC SURGERY METHOD USING NON-CONTACT SCANNING LASER

January 14, 2002

PETITION FOR CERTIFICATE OF CORRECTION DUE TO PATENT OFFICE ERROR

Director of the US Patent & Trademark Office Washington, DC 20231

Sir:

We recently received the original letters Patent RE37,504. However, in our review of the claims of that patent, we note a typographical error in Claim 56. Please correct RE37,504 by issuing the attached Certificate of Correction.

Respectfully submitted,

William H. Bollman Reg. No. 36,457

Manelli Denison & Selter PLLC 2000 M Street, NW Suite 700 Washington, DC 20036-3307 TEL. (202) 261-1020 FAX. (202) 887-0336

GERTIFICATE

JAN 1 6 2002

G CORRECTION



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

DATE:

January 2, 2003

TO:

Certificates of Correction Branch

FROM:

Linda Dvorak

SPE, Art Unit 3739

SUBJECT: REQUEST FOR CERTIFICATE OF CORRECTION

Please issue a Certificate of Correction in U. S. Letters Patent No. RE37,504 as specified on the-attached Certificate.

Linda Dvorak, SPE

Art Unit 3739

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE

Patent No. RE37,504 Patented: January 8, 2002

It is requested that the first line of the specification of this patent be amended to make reference to a Continuing Reissue application which claims the benefit of the instant patented file. The first line of the specification of the patent should be amended to read as follows:

"This application is a continuation-in-part application of Serial No. 07/985,617, filed December 3, 1992, now abandoned. This application is also related to U.S. Serial No. 10/034,929, filed January 4, 2002 which is a continuation application of the instant patented file."

Linda Dvorak

Supervisory Patent Examiner,

Art Unit 3739

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : RE 37,504 E

DATED : January 8, 2002

INVENTOR(S) : Lin

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 21,

Line 62, change "claim 54" to -- claim 68 --.

Signed and Sealed this

Twenty-seventh Day of May, 2003

JAMES E. ROGAN
Director of the United States Patent and Trademark Office

Approved for use through 01/31/2004. OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE **CERTIFICATE OF CORRECTION**

PATENT NO : US RE37,504

DATED

January 8, 2002

INVENTOR(S):

Lin

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Holine 627

Line 2 change "claim 54" to -- claim 68 --.


MAILING ADDRESS OF SENDER: William H. Böllman, Esq. Manelli Denison & Selter PLLC 2000~M Street, NW Suite 700 Washington, DC 20036--3307

PATENT NO. US RE37,504

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



4193985

ADDESECTOR ACTOR SALVA PROGRESSION OF THE PROGRESSI

TO ALL TO WHOM THESE PRESENTS SHALL COME:

Migroug. There has been presented to the

Commissioner of Patents and Trademarks

a petition praying for the grant of Letters Patent for an alleged NEW AND USEFUL INVENTION THE TITLE AND DESCRIPTION OF WHICH ARE CON-TAINED IN THE SPECIFICATIONS OF WHICH A COPY IS HEREUNTO ANNEXED AND MADE A PART HEREOF, AND THE VARIOUS REQUIREMENTS OF LAW IN SUCH CASES MADE AND PROVIDED HAVE BEEN COMPLIED WITH, AND THE TITLE THERETO IS, FROM THE RECORDS OF THE PATENT AND TRADEMARK OFFICE IN THE CLAIMANT(S) INDICATED IN THE SAID COPY, AND WHEREAS, UPON DUE EXAMInation made, the said $\operatorname{Claimant}(s)$ is (are) adjudged to be entitled to : A PATENT UNDER THE LAW.

Now, therefore, these Lefters Patent are to grant unto the said CLAIMANT(S) AND THE SUCCESSORS, HEIRS OR ASSIGNS OF THE SAID CLAIMANT(S) FOR THE TERM OF SEVENTEEN YEARS FROM THE DATE OF THIS GRANT, SUBJECT TO THE PAYMENT OF ISSUE FEES AS PROVIDED BY LAW, THE RIGHT TO EXCLUDE THERS FROM MAKING, USING OR SELLING THE SAID INVENTION THROUGHOUT THE TED STATES.

> In testimony whereof Thave hereunto set my hand and caused the seal of the Patent and Trademark Office to be affixed at the City Vashington this eighteenth day March in the year of our Lord one of Washington this thousand nine hundred and eighty, and of the Independence of the United States l America the two kundred and fourth.

accel Silying A. Diamond

Commissioner of Patents and Trademarks.

United States Patent [19]

Bechgaard et al.

[11] **4,193,98**

[45] Mar. 18, 1980

			•		
[54]	MULTIPL	E-UNITS DRUG DOSE	3,444,290	5/1969 7/1971	Wai Frei et
[75]	Inventors:	Helle Bechgaard, Hellerup; Arne M.	3,592,185 3,608,061		McNal
ניין	Zii veii (ei e	Pedersen, Vanlose, both of Denmark	3,775,537		
			3,917,813	11/1975	Pederse
[73]	Assignee:	A/S Alfred Benzon, Copenhagen, Denmark	FO	REIGN	PATEN
[21]	Appl. No.:	889,269	42-25410	12/1967	Japan
	• •		42-25412		Japan
[22]	Filed:	Mar. 23, 1978	41-10798-		Japan
[30]	Foreig	n Application Priority Data	41-10799 44-27839		Japan Japan
		B] United Kingdom 13296/77	48-24246		Japan
IVIA					•
[51]	Int. Cl. ²	A61K 9/22; A61K 9/54	Primary Es		-
[52]	U.S. Cl		Attorney, A	gent, or r	
	42	4/14; 424/16; 424/20; 424/32; 424/33; 424/35	[57]		ABSTE
[58]	Field of Se	arch 424/24, 14, 16, 19–22,	A control	led relea	se multip
[30]	Field of Se	424/32, 33, 35	scribed, wl	hich com	prises a t
			a plurality	of subuni	its, each c
[56]	References Cited active agent and being e				
	U.S. 1	PATENT DOCUMENTS	brane allov	_	
2 8	01,203 7/19	957 Leb et al 424/4	testinal tra	•	
	17,329 1/19		creased sp		_
	56,724 10/19		weight of	the activ	e agent.
	41,417 9/19				Mataua Br
3,3	68,944 2/19	968 Sandmark et al 424/4		4 (Jaims, No

A controlled release multiple-units drug dose is described, which comprises a tablet or a capsule enclosing a plurality of subunits, each containing a therapeutically active agent and being enclosed in an insoluble membrane allowing for diffusion of the juices of the gastrointestinal tract, at least some of the subunits being of increased specific weight as compared with the specific weight of the active agent.

4 Claims, No Drawings

MULTIPLE-UNITS DRUG DOSE

This invention relates to oral drug depot formulations of the multi-units type with a controlled release action 5 of short or long duration of the active agent or agents. A multiple-units dose consists of a great number of subunits, usually in the form of pellets or microencapsulated crystals contained in a capsule or tablet.

Oral depot products can be formulated according to 10 two different principles: The controlled release singleunit dose or the multiple-units dose.

A single-unit dose, e.g. a matrix tablet or a tablet enclosed in a diffusion membrane, is a depot which releases a drug during the passage of the entire alimentary canal without disintegrating. The empty core or shell is discharged.

A multiple-unit dose consists of a large number of mini-depots, e.g. pellets or microencapsulated crystals, contained in a capsule or a tablet. These many subunits 20 are dispersed and distributed throughout the gastrointestinal tract when the capsule or tablet disintegrates.

An adjustment of the release rate of the depot according to its transit time through the small intestine is essential to the achievement of a satisfactory bioavailability, as the greatest absorption capacity is generally possessed by this part of the gastrointestinal tract, particularly the jejunum and the proximal ileum.

Single-unit doses tend to follow the food having a 30 normal transit time through the small intestine that varies between 3 and 8 hours. Accordingly, 6-10 hours are recommended by many authors as the maximum duration of in vitro release from depot formulations.

drug depot in the upper gut in order (i) to assure optimal absorption or (ii) to additionally extend the absorption phase. The latter applies e.g. to drugs with biological half-lives requiring an absorption period of more than 6-10 hours to facilitate a lower dosage frequency (once 40 daily) and thus a more secure therapy.

As the subunits of the multiple-units formulations are distributed freely throughout the gastrointestinal tract, their transport is to a greater extent independent of the products is less vulnerable to variations in both gastric emptying and intestinal transit time, providing a more secure interaction between in vitro release and bioavailability and thus a better reproducible effect.

Accordingly, the multiple-units dose principle is ex- 50 pected to facilitate the production of drug depots with a reproducible and predetermined prolonged intestinal

Obviously, it would be advantageous if the absorption period could be extended in order to reduce the 55 frequency of drug administration to, for example, once daily, thus improving patient compliance and reducing the risk of erroneous administration.

The invention is based upon the observation that the specific weight of the subunits in a multiple-units dose 60 greatly influences the average transit time of the subunits through the gastrointestinal tract.

A pilot study showed that in the same patient an increase by 0.6 g/ml in the specific weight of the subunits (pellets or microencapsulated crystals) in a multi- 65 ple-units dose increased the transit time of the subunits through the gastrointestinal tract up to 5 times, irrespectively of the size of the subunits.

An object of the invention is thus to utilize this discovery to obtain a reproducible, prolonged transit time, through the gastrointestinal tract, of the subunits of a multiple-units dose.

According to the invention, therefore, a controlledrelease multiple-units drug dose comprises a tablet or capsule enclosing encapsulated pellets, granules or crystals of a therapeutically active agent, the specific weight of at least some of which has been increased to a specific weight of at least 1.4 by means of a physiologically inert or innocuous substance of higher specific weight than that of the therapeutically active agent.

The said increase of the specific weight ensures that the units get a specific weight exceeding that of the

The increase can be attained e.g. by incorporating the physiologically inert or innocuous substance in the core or the coating material of the pellets or the coating material of the microencapsulated crystals, or in any other known way.

Examples of substances, which can be used to increase the specific weight of the subunits in a controlled-release multiple-units dose, are barium sulphate, zinc oxide, titanium dioxide, and iron powder produced by reduction (ferrum reductum).

The use of a controlled-release multiple-units dose is also advantageous because dispersal of the subunits along the gastrointestinal tract results in lower local concentration of the active substance, thus causing less irritation of the mucosa in case of irritative drugs.

Since a greater specific weight tends to increase the transit time of the subunits, obviously a combination of lighter and heavier subunits in a multiple-units dose has the effect of further dispersing the units along the gas-In some cases it is desirable, however, to retain the 35 trointestinal tract. Mixing of subunits of different specific weight and/or with different active agents could also be advantageous in the formulation of a controlledrelease multiple-units combined product.

The controlled, prolonged drug release means also that unnecessary peak concentrations in the blood with their inhérent risks of exaggerated drug action or enhanced side effects of both are avoided and that adequate treatment over extended time periods is ensured.

Clinical investigations have shown that the transit transit time of food. Hence the bioavailability of these 45 time of the individual units of a multiple-units dose can easily be extended over a 24 hours period by suitably increasing the specific weight of the subunits.

Thus, according to the invention, a substantial proportion, e.g. at least 5% and preferably at least 20%, and sometimes at least 50%, by weight of the total composition is in the form of subunits having specific weight greater than the specific weight of the entire drug composition. The amount by which the specific weight of some of the subunits is above the average can vary widely, but preferably it is at least 5% above the average and preferably at least 20%. Expressed in another way at least 25% by weight of the subunits preferably have a specific weight at least 25% above the specific weight of other subunits in the composition.

Although the drug release from the subunits of the multiple-units dose can be controlled in various known ways, the preferred manner of controlling is by coating the subunits with a diffusion membrane which is insoluble in and not degradable by the gastrointestinal juices.

The subunits can be composed as follows. An inactive, heavy core can be provided with a layer of the active agent by means of a suitable adhesive, and then provided with a diffusion membrane.

25

50

55

Alternatively, the active agent can be mixed with the innocuous heavy substance, the mixture being formed to pellets or granules, and coated with the diffusion membrane.

A third possibility is using crystals of the active agents as cores in the subunits.

In all cases, the amount and specific weight of the inactive substance determines the increase in specific weight of the subunits.

A pilot study was aimed at observing the influence on transit time of variations in specific weight and size of the subunits. Four ileo-colostomy patients, three females and one male, aged between 24 to 40 years, three with part of the small intestine resected, volunteered for the study. The post-operative period was from 2 to 6 months. As determined the day before the investigation, each patient had a gastrointestinal transit time of at least 2½ hours.

Coated pellets were used, prepared either with barium sulphate (specific weight of pellets 1.6 g/ml) or with paraffin wax (specific weight of pellets 1.0 g/ml). In both cases, the diameters were 0.3-0.7 mm and 1.2-1.7 mm, respectively.

After a 12 hours fasting period, a transparent colostomy bag was fitted to the patient, and 1850 pellets suspended in a standard meal were administered. After this meal, the patients resumed the usual hospital meal routine.

The investigation period was 36 hours. During the first 12 hours, the colostomy bag was totally emptied every 3 hours, during the next 12 hours intermittently as needed, and during the final 12 hours again every 3 35 hours.

The contents from each emptying were investigated separately, counting the contents of the four different types of pellets to determine the transit time.

The following tables illustrate the results of the investigations.

Table 1

	1 4016	.1	
Numb	er, size, and specific	weight of the pelle	ets
Number of	Diar	neter	
pellets	0.3-0.7 mm	1.2-1.7 mm	Total
Light pellets sp.w. 1.0 g/ ml Heavy pellets sp.w. 1.6 g/	800	125	925
ml	800	125	925
	1600	250	1850

Table 2

Recovery of pellets				
		Dias	neter	
Patient	Sp. weight	0.3-0.7 mm	1.2-1.7 mm	
EBO	1.0	87.9%	98.4%	_
	1.6	95.6%	96.0%	
IMC	1.0	88.9%	95.2%	
	1.6	64.9%	64.8%	
MH	1.0	76.1%	67.2%	
	1.6	71.3%	41.6%	
PKB	1.0	89.8%	95.2%	
	1.6	72.5%	77.6%	

Table 3

		Averag	e tran	sit time	for pe	llets in	hours		
		EI	30	11	AC	M	H	PK	B1)
Sp.w.	Diam.	0.3- 0.7		0.3- 0.7		0.3- 0.7	1.2-	0.3- 0.7	1.2- 1.7
1.0 1.6		3.2 13.5	1.8 9.5	6.5 23.7	7.9 27.3	12.9 16.0	16.9 19.3	9.0 10.7	9.8 10.1

¹⁾One colostomy bag was lost during the 5th interval of the investigation period. The number of each type of pellets in the lost bag has been calculated on the assumption that the probability of recovery would be equal to that of EBO.

The extension of the transit time attained by an increase of the specific weight of the pellets is clearly demonstrated by Table 3.

Continued clinical investigations comprised six ileocolostomy out-patients, five females and one male, aged between 25 and 50 years. Two of the patients had part of the ileum resected.

Participation in the study was conditional upon the patient having terminated a post-operative period of 2 months and having a transit time at least 3 hours, as determined on the day before the examination.

Coated peliets identical to those in the pilot study were used.

In the morning of the day of examination, the fasting (12 hours) ileo-colostomy patient had a transparent colostomy bag fitted, and at the same time 250 peilets of each of the four kinds, or a total of 1000 pellets, were administered, suspended in a standard meal.

After the test meal, the patient resumed the usual meal and locomotive routine. The colostomy bag was emptied completely every 2 hours during the first 14 hours, and then every 4 hours during the following 8 hours of night. The pattern of emptying was repeated the following day in order to complete a 48 hours' observation period.

The collected fractions were analysed by manually picking off the pellets from thin layers of the visceral contents.

40 The frequency of pellets in the colostomy bags during the first day, defined as the period from 8 a.m. to 2 a.m., is shown in Table 4. The difference in frequencies of the four types of pellets having passed the small intestine during the first day is seen to be caused mainly by the differences in specific weight of the pellets, the influence of the different diameters of pellets being less important.

Table 4

	quency (9 Spe-	-/						
Size	cific			Patien	ts			Ave-
mm	weight	BMM	VN	AS(2)	HB	JPL	10(3)	rage
0.3-0.7	1.0	100.0	100.0	91.9	90.4	100.0	97.7	97.6
	1.6	17.2	6.3	77.0	9.8	16.4	16.6	13.3
1.2-1.7	1.0	99.1	99.6	99.2	77.2	96.3	87.6	92.1
	1.6	10.9	4.4	68.8	2.1	3.4	5.4	5.2

(1) Relative to recovered pellets. The average of recovered pellets of all four kinds in the total observation period was 90% (range 84-95%). (2) The patient AS is atypical, owing to a very large consumption of liquid, totalling

⁽²⁾The patient AS is atypical, owing to a very large consumption of liquid, totallin 5900 ml (thereof 5000 ml of beer), during the test period.

60 (3) The figures for the patient 10 is the average of two replicate studies.

The figures shown that the specific weight is of significant importance (p<0.05) for the prolongation of the transit time of the subunits, whereas it is doubtful whether an increase in size if of importance.

The following Examples illustrate different ways of preparing pellets with increased specific weights for use in controlled-release multiple-units doses.

EXAMPLE 1

The components of the core of a pellet are:

·	Parts by weigh
Ferrum reductum	80
4-(2-Hydroxy-3-isopropylaminopropoxy)-indole	6
Microcrystalline cellulose	6
Talcum	2
Hydroxypropylcellulose	3
Sodium hydrogen carbonate	3

The components are mixed and moistened with 20 parts by weight of water, after which the mass is extruded to form strings of 1 mm diameter, from which balls of approximately 1 mm diameter are formed. After drying, the specific weight of the balls is 3.7.

The balls are coated with a solution of an acrylic polymer, marketed under the registered trade mark Eudragit RS, the specific weight being 3.4 after the coating.

EXAMPLE 2

The core components of a pellet are:

	Parts by weight	
Zinc oxide	95	
Polyethylene powder	5	

The components are mixed, moistened with 16 parts by weight of water, and extruded to strings of 0.8 mm diameter, from which balls with about the same diameter are formed. After drying, the specific weight of the 35 balls is 3.0.

The cores are then coated with 15 parts by weight of ethylphenylephrine hydrochloride (\alpha-[(ethylamino)inethyl]m-hydroxybenzyl alcohol hydrochloride) by alternatively moistening with a 3% solution of ethylcellu- 40 lose in isopropanol and coating with the powdered drug.

Finally, an external coating is applied, consisting of ethylcellulose with 10% by weight of acetyltributyl citrate admixed as a softening agent.

The specific weight of the resulting pellets is 2.7.

EXAMPLE 3

The components of the subunits are:

	Parts by weight
Acetylsalicylic acid crystals	65
Titanium dioxide	32.5
Acrylic polymer (Eudragit ® RS)	2.5

In a coating pan, the crystals of acetylsalicylic acid (specific weight 1.37) are alternatively moistened with a 10 3% solution of the acrylic polymer, and dusted with titanium dioxide powder.

The specific weight of the resulting coated crystals is 1.6.

1. A controlled release upper-gut retentive gastrointestinal tract transit time increasing multiple-units drug dose, which comprises a tablet or a capsule, enclosing subunits of a therapeutically active agent in the form of 0.3 to 1.7 millimeter balls or pellets, each of which are enclosed in an insoluble dialysis membrane of a cellulose ether or acrylic polymer allowing for diffusion of the juices of the gastrointestinal tract, the specific weight of at least 25% by weight of which subunits has been increased from 1.0 or less to at least 1.4 by means 25 of a physiologically innocuous substance of higher specific weight than that of the therapeutically active

2. A controlled release upper-gut retentive gastrointestinal tract transit time increasing multiple-units drug dose, which comprises a tablet or a capsule, enclosing subunits of a therapeutically active agent in the form of spherical 0.3 to 1.7 millimeter balls or pellets, each of which are enclosed in an insoluble dialysis membrane of ethyl cellulose or acrylic polymer allowing for diffusion of the juices of the gastrointestinal tract, the specific weight of at least 25% by weight of which subunits has been increased to at least 1.4 by means of barium sulfate, zinc oxide, titanium dioxide or ferrum reductum, as a physiologically innocuous substance of higher specific weight than that of the therapeutically active agent, and the other subunits in the drug dose have an otherwise unchanged specific weight of 1.0 or less.

3. A drug dose as set forth in claim 2, in which the specific weight of at least some of the subunits is at least 45 1.6.

4. A drug dose as set forth in claim 2, in which subunits of different specific weights contain different therapeutic agents.

50

55

65

DEPARTMENT OF COMMERCE



UNITED STATE

Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER

OF PATENTS AND TRADEMARKS Washington, D.C. 20231

DATE: 05/02/94

TO:

N05B

WILLIAM M. HOBBY, III, ESQ. HOBBY & BEUSSE 157 E. NEW ENGLAND AVENUE SUITE 375 WINTER PARK, FL 32789

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE U.S. PATENT AND TRADEMARK OFFICE ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT ASSIGNMENT PROCESSING SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT BRANCH, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231

ASSIGNOR:

LIN, J.T.

DOC DATE: 03/25/94

RECORDATION DATE: 03/25/94 NUMBER OF PAGES 002 REEL/FRAME 6939/0975

DIGEST: ASSIGNMENT OF ASSIGNORS INTEREST

ASSIGNEE:

PATENT NUMBER

LASERSIGHT, INC. 3251 PROGRESS DRIVE SUITE B ORLANDO, FL 32826

SERIAL NUMBER 8-218319

FILING DATE 03/25/94 ISSUE DATE 00/00/00

EXAMINER/PARALEGAL ASSIGNMENT BRANCH

ASSIGNMENT/CERTIFICATION SERVICES DIVISION


RECEIVED

MAY 2 6 94

W. M. HOBBY

1994	PATENTS ON	Office LY	U.S. DEPARTMENT \$310
THE WAR COMMISSIONER OF Patents and Tr	ademarks: Please record	the attached documents	OF copy thoroas
1.) Name of conveying party(J.T. LIN	ies): (2.) Na		of receiving
Additional name(s) of corparty(ies) attached?Ye	. I	nternal Addres	
Nature of conveyance: X_AssignmentSecurity		treet Address: ity: Orlando	3251 Progress Drive Suite B
Merger	Z:	ip: 32826	State: FL
Execution Date: March 25, Application number(s) or p			(s) & address(es)
If this document is being f date of the application is			
A. Patent Application No.		B. Patent No.	
Additiona	al numbers atta	ached? ve	s X No A
Name and address of party whom correspondence conce document be mailed:	to 6 Toterning pat	cal number of a cents involved	applications and E
William M. Hobby, III, Es			FR 3.41)\$ 40.06
<u>Internal Address:</u> Hobby & Beusse	·	X Enclosed	l '
157 E. New England Avenue Suite 375 Winter Park, FL 32789	position .	depos1	zed to be charged to t account
Street Address: Same as ab		eposit account	
100 MG 04/06/94 08218319	1 501	ch duplicate copy of thi	is page if paying by deposit account)
Statement and signature	OO NOT USE THIS SPACE		93135561
correct and any attached copy illiam M. Hobby, III	Il XVI	foregoing inf	nar document.
ime of Person Signing Sig	nature Wooding of pages including of	over sheet, attachment	Date





- 4	_
-	
•	,

Dr. J.T. Lin hereinafter referred to as assignor, has made certain improvements or inventions in OPHTHALMIC SURGERY METHOD USING NON-CONTACT **SCANNING LASER** for which said assignor has executed an application for United States Letters Patent on the 25th day of _1998⁴; and

WHEREAS, LaserSight, Inc. hereinafter referred to as assignee, is desirous of acquiring the same;

NOW THEREFORE, This Indenture Witnesseth: That for and in consideration of ONE DOLLAR, lawful money of the United States and other good and valuable consideration, receipt whereof is hereby acknowledged, said assignor does hereby sell, assign, and transfer to said assignee, its successors and assigns, all right, title and interest in and to said U.S. Patent Application, the invention or inventions therein shown and described and any improvements on said inventions heretofore or hereafter made, any divisions of continuations of said application, and all patents, United States and foreign, to be granted upon any such application, or for the invention or inventions thereof, and any reissues, continuations or extensions of said patents; and said assignor does hereby authorize and request the Commissioner of Patents to issue all patents on said United States Patent applications or for the invention or inventions hereof, in accordance with this assignment.

And said assignor for said consideration hereby covenants and agrees that said assignor is the owner of the full title herein conveyed and has the right to convey the same, and agrees that said assignor will communicate to said assignee, any facts known to said assignor respecting said invention or inventions, and testify in any legal proceedings when called upon by said assignee, sign all lawful papers deemed by said assignee as expedient to vest in it the legal title herein sought to be conveyed or for the filing and prosecution of all applications and patents, United States and foreign, and otherwise aid said assignee, its successors and assigns, in obtaining full patent protection on said invention and enforcing proper protection under said patents, but in every instance at the assignee's expense

Signed and sealed this day of MALCH

HERT & IRADEMARK OFFICE

STATE OF FLURIDA: COUNTY OF ORANGE : MAR 25 94

The foregoing instrument was acknowledged before me this 25 , 1994 by Dr. J.T. Lin, who vis personally known of who has produced as identification and who did/did not take an oath.

NOTARY PUBLIC

My Commission Expires:



OFFICIAL SEAL WILLIAM M. HOBBY My Commission Expires Feb. 16, 1996 Comm. No. CC 180901